in this issue
Pharma/Fine Chemicals Roundup – September 25
8:30 AM MDT | September 25, 2012 | By DEEPTI RAMESH
FINE CHEMICALS: STAYING ACTIVE
The global active pharmaceutical ingredient (API) industry is very competitive, and manufacturers are faced with several challenges, including pricing pressure, rising costs, and increasingly stringent regulations related to quality and environment. Nevertheless, the industry says the outlook is favorable, and that a new law in U.S. is expected to create a level playing field for U.S. and global API manufacturers.
APIS WILL DRIVE GROWTH IN CONTRACT MANUFACTURING
Manufacturing of active pharmaceutical ingredients (APIs) will account for the majority of revenues in the pharmaceutical contract manufacturing industry in the next 10 years, says a recent report by business information provider Visiongain (London). The report predicts that the global market for pharmaceutical contract manufacturing will be worth $47.6 billion in 2012; and between 2011 and 2016, the overall market will grow at a compound annual growth rate of over 6%. API manufacturing formed the largest sector in pharmaceutical contract manufacturing in 2011, accounting for more than two-thirds of revenues. Increased demand for generic drugs will drive revenue growth for emerging-market contract manufacturing organizations, and highly potent API manufacturing will drive growth in U.S. and Europe, the report says
CARBOGEN AMCIS PARTNERS WITH ADC BIOTECHNOLOGY
Carbogen Amcis (Bubendorf, Switzerland), a pharma process-development and active pharmaceutical ingredient (API) manufacturing subsidiary of Dishman Pharmaceuticals and Chemicals (Ahmedabad, India) says it has entered into a collaboration with ADC Biotechnology (Denbighshire, U.K.) to provide customers with seamless development and manufacturing services for antibody-drug conjugates (ADCs)— key anticancer treatment platform.
PCAS OPENS NEW OFFICE IN U.S., APPOINTS PRESIDENT OF PCAS AMERICA
PCAS (Longjumeau, France), a fine and specialty chemicals company and a leading manufacturer of active pharmaceutical ingredients (APIs), says it has recently opened a new North American office at Hoboken, NJ. The company also announced the appointment of Laurent Alexandre as president of PCAS America and Donald LaFerle as senior v.p./custom synthesis and pharma chemicals in U.S. PCAS America was established in 2004, and develops and produces pharma chemicals and APIs for both emerging innovators and multinational pharmaceutical firms. PCAS recorded total sales of €164.5 million ($212 million) in 2011, and sales in North America accounted for 10.1% of that total.
Alexandre, the new president of PCAS America, comes to U.S. after working for many years at the PCAS headquarters in France, where he was and will continue to be responsible for global business development of PCAS’s generic API business, the company says. LaFerle has 23 years of experience in life-science sourcing, procurement, business development, sales, and marketing, PCAS says.
ALCHEM EXPANDS CAPACITY OF PHYTOCHEMICALS SITE
Alchem International (Ballabgarh, India), a manufacturer of phytochemicals for medicinal and cosmetic use, says it has opened its expanded facility at Neemrana, India; this site produces sennosides USP, an active pharmaceutical ingredient. Sennosides, extracted from senna leaves and pods, are used as laxatives in traditional and modern medicine preparations. “Expansion of our facility was necessary to answer the growing demand for 60% USP Sennosides. The fully automated facility has a production capacity of more than 75 m.t./year,” says Raman Mehta, president of Alchem.